Skip to main content

Profiles

Amanda Cohn

Dr. Amanda Cooper Cohn, MD, is an American pediatrician based in Atlanta, Georgia.[1] She is the director of the Division of Birth Defects and Infant Disorders within the National Center for Birth Defects and Developmental Disabilities (NCBDDD) at the Centers for Disease Control and Prevention (CDC).[2] In this role, she acts as a liaison representative on Canada's National Advisory Committee on Immunization (NACI).[3]

Cohn is a Commander in the United States Public Health Service.[4]

Background

Cohn is board certified in pediatrics and is a fellow of the American Academy of Pediatrics.[5]

She attended Brown University where she received a Bachelor of Arts in English.[6] She obtained her medical degree from Emory University School of Medicine and completed a residency in pediatrics at Boston Children’s Hospital and Boston Medical Center in Massachusetts.[1:1][7]

Career

Before becoming director of NCBDDD, Cohn previously served as Executive Secretariat of the Advisory Committee on Immunization Practices (ACIP) and Chief Medical Officer for the National Center for Immunization and Respiratory Diseases (NCIRD).[6:1]

Prior to that role, she served as the Acting Director for the National Center on Birth Defects and Developmental Disabilities and Deputy Director for Immunization Services Division for NCIRD.[8][9]

She is the recipient of the CDC 2009 Iain Hardy Memorial Award for “outstanding contributions to vaccine-preventable diseases.”[10]

Cohn has participated on the planning committee for the Forum on Microbial Threats, chaired by EcoHealth Alliance President Peter Daszak.[11][12]

Research

Cohn has co-authored research on meningococcal vaccines.[13]

COVID-19

Cohn was a co-author on the study identifying the first SARS-CoV-2 infection in the United States, published in March 2020 in the New England Journal of Medicine.[14]

  1. Dr. Amanda Cohn Internal Medicine/Pediatrics. Atlanta GA. WebMD. Retrieved April 21, 2022, from http://archive.today/2022.04.21-200802/https://doctor.webmd.com/doctor/amanda-cohn-2867e6ee-0934-4974-ae63-1fe527ee4532-overview ↩︎ ↩︎

  2. National Center on Birth Defects and Developmental Disabilities. (2022, April 15). Biography - Amanda Cohn, MD. Centers for Disease Control and Prevention. http://archive.today/2022.04.21-194520/https://www.cdc.gov/ncbddd/aboutus/biographies/cohn.html ↩︎

  3. National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 14). Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html ↩︎

  4. Cohn, A. (2011, April 6). Amanda Cohn, MD CDR, US Public Health Service National Center for Immunization and Respiratory Diseases April 6, 2011 Epidemiology of Meningococcal Disease - [PPTX Powerpoint]. India Document. http://archive.today/2022.04.21-202549/https://vdocument.in/amanda-cohn-md-cdr-us-public-health-service-national-center-for-immunization.html?page=1 ↩︎

  5. Fellows in the News. (2014). AAP News, 35(7), 32–32. https://doi.org/10.1542/aapnews.2014357-32 ↩︎

  6. CAPT Amanda Cohn. U.S. Food and Drug Administration. Retrieved April 21, 2022, from https://web.archive.org/web/20211108164042/https://www.fda.gov/media/136851/download ↩︎ ↩︎

  7. Mead, A. (2021, May 12). Vaccinating Rural America: Q&A with Dr. Amanda Cohn. The Rural Monitor. https://www.ruralhealthinfo.org/rural-monitor/amanda-cohn-vaccination/ ↩︎

  8. National Center on Birth Defects and Developmental Disabilities (NCBDDD) - Amanda Cohn, MD (CAPT, USPHS). (2020, February 3). Centers for Disease Control and Prevention. http://archive.today/2022.04.21-195616/https://web.archive.org/web/20200404090018/https://www.cdc.gov/about/leadership/leaders/ncbddd.html ↩︎

  9. Capt. Amanda Cohn, MD. (2021). University of New Mexico. https://web.archive.org/web/20210919091328/https://hsc.unm.edu/echo/_docs/covid-global-conversation/1.11.21_cohn_final1.pdf ↩︎

  10. ACIP Updates on Vaccine Recommendations. (2017, November 4). Eventscribe. http://archive.today/2022.04.21-202056/https://www.eventscribe.com/2017/FallCVC/ajaxcalls/PresentationInfo.asp?efp=UUtZS0pIS1Q0MjE0&PresentationID=292709&rnd=0.7055475 ↩︎

  11. Planning Committee on the Critical Public Health Value of Vaccines: Tackling Issues of Access and Hesitancy. (2021). National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK572616/ ↩︎

  12. Forum on Microbial Threats. (2021). The Critical Public Health Value of Vaccines: Tackling Issues of Access and Hesitancy: Proceedings of a Workshop. (J. Liao, C. Minicucci, & A. Nicholson, Eds.). National Academies Press. https://doi.org/10.17226/26134 ↩︎

  13. Terranella, A., Cohn, A., & Clark, T. (2011). Meningococcal conjugate vaccines: optimizing global impact. Infection and Drug Resistance, 4, 161. https://doi.org/10.2147/idr.s21545 ↩︎

  14. Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, S. I., Kim, L., Tong, S., Lu, X., Lindstrom, S., & Pallansch, M. A. (2020). First Case of 2019 Novel Coronavirus in the United States. New England Journal of Medicine, 382(10), 929–936. https://doi.org/10.1056/nejmoa2001191 ↩︎